India - Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced that its step-down, wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.'s oral solid dosage manufacturing facility, located in Cranbury, New Jersey, U.S., effective 1st September, 2023.
The facility is acquired for a total consideration of US $7.7 million. As part of the acquisition, the existing workforce of the facility will transition to Biocon Generics Inc. The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year.
Siddharth Mittal, Managing Director and CEO, Biocon Limited said, 'The acquisition of this US FDA approved facility, our first in the U.S., will complement Biocon's existing manufacturing capabilities and strengthen our foothold in the United States.
The acquisition will also enable us to add oral solid dosage capacities for new products earlier than originally planned and ensure continuity of supply through the diversification of our manufacturing infrastructure.
Our focus will be on integrating the acquired facility expeditiously and expanding our portfolio in the region.'
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.
Contact:
Tel: +91 80 2808 2808
Fax: +91 80 2852 3423
Email: contact.us@biocon.com
Web: www.biocon.com
(C) 2023 Electronic News Publishing, source ENP Newswire
BIOCON LIMITED 
